These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 28604130)

  • 21. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.
    Wang GX; Kurra V; Gainor JF; Sullivan RJ; Flaherty KT; Lee SI; Fintelmann FJ
    Radiographics; 2017; 37(7):2132-2144. PubMed ID: 29131763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint inhibitors for the treatment of melanoma.
    Sabbatino F; Liguori L; Pepe S; Ferrone S
    Expert Opin Biol Ther; 2022 May; 22(5):563-576. PubMed ID: 35130816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
    Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
    Vazquez A
    Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
    Eggermont AM; Maio M; Robert C
    Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.
    Christiansen SA; Khan S; Gibney GT
    Cancer J; 2017; 23(1):59-62. PubMed ID: 28114256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Renaissance of immuno-oncology for urological tumors : Current status].
    Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
    Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Checkpoint Immunotherapy: Picking a Winner.
    Teng MW; Khanna R; Smyth MJ
    Cancer Discov; 2016 Aug; 6(8):818-20. PubMed ID: 27485001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
    Kakavand H; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of melanoma.
    Kee D; McArthur G
    Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune alterations in malignant melanoma and current immunotherapy concepts.
    Shimanovsky A; Jethava A; Dasanu CA
    Expert Opin Biol Ther; 2013 Oct; 13(10):1413-27. PubMed ID: 23930800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Harnessing the immune system for the treatment of melanoma: current status and future prospects.
    Guennoun A; Sidahmed H; Maccalli C; Seliger B; Marincola FM; Bedognetti D
    Expert Rev Clin Immunol; 2016 Aug; 12(8):879-93. PubMed ID: 27070898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives.
    Marra A; Ferrone CR; Fusciello C; Scognamiglio G; Ferrone S; Pepe S; Perri F; Sabbatino F
    Anticancer Agents Med Chem; 2018; 18(2):166-181. PubMed ID: 29256359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions.
    Atkins M
    Semin Oncol; 2015 Dec; 42 Suppl 3():S12-9. PubMed ID: 26598055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma immunotherapy: strategies to overcome pharmacological resistance.
    Trojaniello C; Vitale MG; Scarpato L; Esposito A; Ascierto PA
    Expert Rev Anticancer Ther; 2020 Apr; 20(4):289-304. PubMed ID: 32195606
    [No Abstract]   [Full Text] [Related]  

  • 37. Immune Checkpoint Inhibitors for Brain Metastases.
    Tan AC; Heimberger AB; Menzies AM; Pavlakis N; Khasraw M
    Curr Oncol Rep; 2017 Jun; 19(6):38. PubMed ID: 28417311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
    Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
    Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.
    Vreeland TJ; Clifton GT; Herbert GS; Hale DF; Jackson DO; Berry JS; Peoples GE
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1347-1357. PubMed ID: 27323245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of interferon in melanoma: old hopes and new perspectives.
    Sanlorenzo M; Vujic I; Carnevale-Schianca F; Quaglino P; Gammaitoni L; Fierro MT; Aglietta M; Sangiolo D
    Expert Opin Biol Ther; 2017 Apr; 17(4):475-483. PubMed ID: 28274138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.